Authors
Yuyao Sun, Chenggong Yu, Chaochao Zhang, Ying Li, Wenqing Zhang, Bowei Li, Mengli Song, Lin Wang, Bowen Li, Qingwen Xu
Published in
Materials today. Bio. Volume 41. Pages 103805. Epub Nov 06, 2026.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disorder characterized by excessive extracellular matrix (ECM) accumulation, myofibroblast activation, and chronic inflammation. Current pharmacotherapies are hindered by modest anti-fibrotic efficacy and poor drug accumulation within fibrotic lesions. Herein, we developed an inhalable, collagenase-modified liposomal nanoplatform co-encapsulating methylprednisolone and pirfenidone (termed CMPNPs) to address these limitations. The CMPNPs exhibited favorable physicochemical properties and retained collagenase activity under atomization-induced shear forces, enabling efficient penetration through collagen-dense barriers and enhanced lung accumulation. In vitro, CMPNPs suppressed TGF-β1-induced myofibroblast differentiation and migration, and shifted macrophage polarization away from pro-fibrotic and pro-inflammatory phenotypes. In a bleomycin-induced IPF mouse model, inhaled CMPNPs improved survival, reduced collagen deposition and fibrotic lesions, and demonstrated superior lung retention and anti-fibrotic efficacy compared to intravenous administration. Collectively, this multi-targeted, barrier-penetrating strategy overcomes key bottlenecks of current IPF therapies and offers a promising translatable approach for treating progressive pulmonary fibrosis.
PMID:
43034868
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 16
- Comments 0